RU2008123243A - АГОНИЗМ 5НТ2а-РЕЦЕПТОРА ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЯ ФУНКЦИИ ТЕРМОРЕГУЛЯЦИИ - Google Patents

АГОНИЗМ 5НТ2а-РЕЦЕПТОРА ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЯ ФУНКЦИИ ТЕРМОРЕГУЛЯЦИИ Download PDF

Info

Publication number
RU2008123243A
RU2008123243A RU2008123243/15A RU2008123243A RU2008123243A RU 2008123243 A RU2008123243 A RU 2008123243A RU 2008123243/15 A RU2008123243/15 A RU 2008123243/15A RU 2008123243 A RU2008123243 A RU 2008123243A RU 2008123243 A RU2008123243 A RU 2008123243A
Authority
RU
Russia
Prior art keywords
5ht2a
regulation function
thermal regulation
receptor agonism
treating disturbance
Prior art date
Application number
RU2008123243/15A
Other languages
English (en)
Inventor
Дарлин Коулман ДИЧЕР (US)
Дарлин Коулман ДИЧЕР
Иштван Йозеф МЕРЧЕНТЭЙЛЕР (US)
Иштван Йозеф МЕРЧЕНТЭЙЛЕР
Лиза ЛЕВЕНТАЛЬ (US)
Лиза ЛЕВЕНТАЛЬ
Кимберли Джин САЙП (US)
Кимберли Джин САЙП
Лоренс Томас О`КОННОР (US)
Лоренс Томас О`КОННОР
Терранс Харольд АНДРИ (US)
Терранс Харольд АНДРИ
Original Assignee
Вайет (Us)
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайет (Us), Вайет filed Critical Вайет (Us)
Publication of RU2008123243A publication Critical patent/RU2008123243A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Применение агониста 5НТ2а-рецептора при изготовлении лекарственного средства для лечения и/или профилактики вазомоторной нестабильности. ! 2. Применение по п.1, отличающееся тем, что упомянутый агонист 5НТ2а-рецептора выбран из группы, которую составляют серотонин, гидрохлорид 1-(2,5-диметокси-4-йодфенил)-2-аминопропана (DOI) и гидробромид (±)-2,5-диметокси-4-бромамфетамина (DOB).

Claims (2)

1. Применение агониста 5НТ2а-рецептора при изготовлении лекарственного средства для лечения и/или профилактики вазомоторной нестабильности.
2. Применение по п.1, отличающееся тем, что упомянутый агонист 5НТ2а-рецептора выбран из группы, которую составляют серотонин, гидрохлорид 1-(2,5-диметокси-4-йодфенил)-2-аминопропана (DOI) и гидробромид (±)-2,5-диметокси-4-бромамфетамина (DOB).
RU2008123243/15A 2002-08-15 2008-06-16 АГОНИЗМ 5НТ2а-РЕЦЕПТОРА ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЯ ФУНКЦИИ ТЕРМОРЕГУЛЯЦИИ RU2008123243A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40369202P 2002-08-15 2002-08-15
US60/403,692 2002-08-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005104815/15A Division RU2340333C2 (ru) 2002-08-15 2003-08-14 Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции

Publications (1)

Publication Number Publication Date
RU2008123243A true RU2008123243A (ru) 2009-12-27

Family

ID=31888268

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005104815/15A RU2340333C2 (ru) 2002-08-15 2003-08-14 Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
RU2008123243/15A RU2008123243A (ru) 2002-08-15 2008-06-16 АГОНИЗМ 5НТ2а-РЕЦЕПТОРА ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЯ ФУНКЦИИ ТЕРМОРЕГУЛЯЦИИ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2005104815/15A RU2340333C2 (ru) 2002-08-15 2003-08-14 Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции

Country Status (18)

Country Link
US (1) US20040063721A1 (ru)
EP (1) EP1534258A2 (ru)
JP (1) JP2006500366A (ru)
KR (1) KR20050040921A (ru)
CN (2) CN1674880A (ru)
AU (1) AU2003256430A1 (ru)
BR (1) BR0313624A (ru)
CA (1) CA2494687A1 (ru)
CO (1) CO5690568A2 (ru)
EC (1) ECSP055599A (ru)
GE (1) GEP20074192B (ru)
IL (1) IL166586A0 (ru)
MX (1) MXPA05001803A (ru)
NO (1) NO20051304L (ru)
RU (2) RU2340333C2 (ru)
UA (1) UA81423C2 (ru)
WO (1) WO2004016256A2 (ru)
ZA (1) ZA200501308B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2007136741A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desmethyl-doxepin and methods of using the same to treat sleep disorders
JP2009537553A (ja) 2006-05-19 2009-10-29 ソマクソン ファーマシューティカルズ インコーポレイテッド 睡眠改善のための低用量ドキセピンの使用法
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
AU2007258553A1 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
WO2008085567A1 (en) * 2006-10-04 2008-07-17 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008060397A2 (en) * 2006-11-03 2008-05-22 Noven Therapeutics, Llc Method of treating thermoregulatory disfunction
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
EP2148659A2 (en) * 2007-04-13 2010-02-03 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
WO2009137531A2 (en) * 2008-05-06 2009-11-12 Somaxon Pharmaceuticals, Inc. Compositions and methods related to action of low dosages of doxepin on the h1 and 5-ht2a receptors
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
AU2011223807B2 (en) * 2010-03-02 2016-05-12 Fervent Pharmaceuticals, Llc Methods and compositions for treating or preventing symptoms of hormonal variations
WO2023212244A1 (en) * 2022-04-27 2023-11-02 Tessellate Therapeutics, Inc. Methods of treating 5ht2a receptor-mediated conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
JP2869512B2 (ja) * 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
US5131149A (en) * 1991-06-19 1992-07-21 Lynn C. Thompson Folding knife
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms

Also Published As

Publication number Publication date
CN1674880A (zh) 2005-09-28
NO20051304L (no) 2005-05-06
ECSP055599A (es) 2005-07-06
CN101099734A (zh) 2008-01-09
CA2494687A1 (en) 2004-02-26
RU2340333C2 (ru) 2008-12-10
CO5690568A2 (es) 2006-10-31
JP2006500366A (ja) 2006-01-05
WO2004016256A3 (en) 2004-06-17
WO2004016256A2 (en) 2004-02-26
AU2003256430A1 (en) 2004-03-03
UA81423C2 (en) 2008-01-10
US20040063721A1 (en) 2004-04-01
KR20050040921A (ko) 2005-05-03
BR0313624A (pt) 2005-06-21
GEP20074192B (en) 2007-09-10
EP1534258A2 (en) 2005-06-01
IL166586A0 (en) 2006-01-15
RU2005104815A (ru) 2005-08-27
ZA200501308B (en) 2009-09-30
MXPA05001803A (es) 2005-08-16

Similar Documents

Publication Publication Date Title
RU2008123243A (ru) АГОНИЗМ 5НТ2а-РЕЦЕПТОРА ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЯ ФУНКЦИИ ТЕРМОРЕГУЛЯЦИИ
BG102637A (en) Tropane derivatives, their preparation and application
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
NO980919L (no) 8-azabicyklo(3.2.1)okt-2-ene derivater, og deres anvendelse til fremstilling av et legemiddel
PL351963A1 (en) Method of treating eating disorders
UA41254C2 (uk) ПОХІДНЕ ТЕТРАГІДРОКАРБАЗОЛУ АБО ЙОГО СІЛЬ, СОЛЬВАТ АБО ГІДРАТ ЯК АГОНІСТ 5-НТ<sub>1</sub>-ПОДІБНОГО РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
DE69728883D1 (de) Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
ES2108700T3 (es) Derivados de diazabiciclonolilo como antagonistas del receptor 5-ht3.
NO20042141L (no) Terapeutiske quinolonforbindelser med 5-HT-antagonistiske egenskaper
DK0788481T3 (da) Fremgangsmåde til fremstilling af levobupivacain og analoger deraf
PL326448A1 (en) Condensed derivatives of thopane, method of obtaining them and their application
FI982572A0 (fi) Aryylisubstituoituja syklisiä amiineja selektiivisinä dopamiini-D3-ligandeina
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister
ES2128668T3 (es) Agonistas del receptor de 5-ht4.
NO20045126L (no) N-acyl piperidinderivater for anvendelse som melanokortinreseptorligander i behandling av fodeforstyrrelser
DE60312474D1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
ATE423555T1 (de) Verwendung von beta-3-adrenergen-rezeptoren agonisten in der behandlung von dysurie
ES2082639T3 (es) Derivados del indol como agonistas de los receptores similares a 5-ht1.
NO983100L (no) 4,5-dihydronaft£1,2-C|isoksazoler og derivater derav med CNS-aktivitet
NZ508152A (en) Phenylsulfonamide-phenylethylamines useful as dopamine receptors
CA2288533A1 (en) New 4-substituted piperidines
DK1107744T3 (da) Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi
HUP0401563A2 (hu) Új piperidinarboxamid-származékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
IS8388A (is) Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110617